Supernus Pharmaceuticals (NASDAQ:SUPN) Releases Quarterly Earnings Results, Beats Estimates By $0.25 EPS

Supernus Pharmaceuticals (NASDAQ:SUPN) announced its earnings results on Monday. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.25, Briefing.com reports. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.94%. The company had revenue of $175.70 million during the quarter, compared to the consensus estimate of $157.35 million. During the same period last year, the firm earned ($0.29) earnings per share. Supernus Pharmaceuticals’s revenue was up 14.2% compared to the same quarter last year. Supernus Pharmaceuticals updated its FY 2024 guidance to EPS.

Supernus Pharmaceuticals Price Performance

SUPN traded down $0.74 during trading hours on Thursday, reaching $37.01. The company’s stock had a trading volume of 222,625 shares, compared to its average volume of 449,435. Supernus Pharmaceuticals has a fifty-two week low of $23.47 and a fifty-two week high of $39.37. The stock has a market cap of $2.04 billion, a PE ratio of 35.28 and a beta of 0.86. The business’s 50-day moving average is $33.08 and its 200-day moving average is $30.59.

Analyst Upgrades and Downgrades

SUPN has been the subject of a number of research analyst reports. StockNews.com upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Cowen restated a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Finally, Piper Sandler reissued a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.